Navigation Links
Orchestra Therapeutics Announces New Phase II Clinical Data on,NeuroVax Demonstrating Marked Expansion of Regulatory T Cell,Populations in Patients With Multiple Sclerosis

d diminished levels of Foxp3+ Treg responses with the pathogenesis and progression of MS. This same mechanism appears to be important in the pathogenesis of other autoimmune diseases such as RA and psoriasis.

About the Study

These new mechanistic clinical data are from a recently completed open- label study examining immunological and clinical parameters in 27 NeuroVax(TM) treatment-naïve and nine previously NeuroVax(TM) vaccinated subjects with various forms of MS. Study participants received monthly injections of NeuroVax(TM) over a one year period.

About OHSU

Oregon Health & Science University, located in Portland, OR., includes the schools of dentistry, medicine, nursing and science and engineering; OHSU Hospital and Doernbecher Children's Hospital; numerous primary care and specialty clinics; multiple research institutes; and several outreach and community service units.

About Orchestra Therapeutics

Orchestra Therapeutics, Inc., formerly The Immune Response Corporation , is an immuno-pharmaceutical company focused on the discovery and development of novel treatments for autoimmune diseases. The Company's lead immune-based therapeutic product candidate is NeuroVax(TM) for the treatment of MS. In addition to MS, the Company has proprietary technology and prior clinical experience for evaluation of TCR peptide-based immune therapies for RA and psoriasis.

The Company also has two HIV product candidates, Remune(R) and IR103. The 52-week data from the first large cohort of HIV clinical trial participants from a now-terminated Phase II clinical trial have already been gathered, and analysis of the data will be completed and disclosed in the second quarter of 2007. Based on this data, the Company will consider strategic alternatives for the HIV program.

The targeted strategy behind the Company's immune-based therapies is reflected in the name Orchestra. Rather than disrupting the function of the e
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
2. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
3. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
4. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
5. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
6. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
7. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
8. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
9. Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From Breast Cancer
10. Trophos Publishes ALS Article in Journal of Pharmacology and Experimental Therapeutics
11. Novelos Therapeutics Announces Encouraging Results in Ongoing Phase 2 Ovarian Cancer Trial at Dana-Farber/Partners Cancer Care
Post Your Comments:
(Date:7/23/2008)...nds Some Areas of the Body Have Greater Concentrat... 23 /PRNewswire-USNewswire/ -- Fat removed,from th...n was found to be,an excellent source of stem cell... areas of the body, reports a Brazilian-based stud...), the official medical journal of the,American So...
(Date:7/22/2008)...tralia, July 22 /- Followin... the Board of Progen,Pharmaceuticals Limited (ASX:...scontinued the PI-88 phase 3 study in liver cancer...lop its existing portfolio of compounds and,the co...pounds and,opportunities through Merger & Acquisit...
(Date:7/22/2008)...g to Discuss Development Plan Completed Successful...l/ -- Amarin Corporation,plc (NASDAQ: AMRN ) toda...icials at the U.S. Food and Drug Administration (F...01 for the treatment of,hypertriglyceridemia. Foll... to Phase 3 with AMR101 in hypertriglyceridemia., ...
(Date:7/22/2008)...llan Will Stress the Importance to Patients of Pas...al Pathway, RICHMOND, Va., July 22 /PRNewswire-Fi...per of follow-on biologics and biopharmaceuticals,...f Insmed, will present at a,Congressional briefing...cant need for establishing an approval pathway for...
Breaking Medicine Technology:Want a Reason to Love Your Lower Belly Fat? It's Rich in Stem Cells 2Progen Terminates PATHWAY Trial & Confirms Focus on Potential High Value Molecules and M&A 2Progen Terminates PATHWAY Trial & Confirms Focus on Potential High Value Molecules and M&A 3Amarin Proceeding to Phase 3 With AMR101 for Hypertriglyceridemia 2Amarin Proceeding to Phase 3 With AMR101 for Hypertriglyceridemia 3Insmed CEO to Present at Congressional Briefing on Follow-On Biologics 2Insmed CEO to Present at Congressional Briefing on Follow-On Biologics 3Kendle Invites You to Attend Its Fourth Quarter and Year End 2007 Earnings Conference Call and Webcast 10496 1Kendle Invites You to Attend Its Fourth Quarter and Year End 2007 Earnings Conference Call and Webcast 10496 2Markets of biodiversity and equity in trade 3A An illusion 3F 2058 1Markets of biodiversity and equity in trade 3A An illusion 3F 2058 2Markets of biodiversity and equity in trade 3A An illusion 3F 2058 3American Journal of Disaster Medicine Accepted for Inclusion into The National Library of Medicines MEDLINE Database and may now be Accessed Through t 10495 1American Journal of Disaster Medicine Accepted for Inclusion into The National Library of Medicines MEDLINE Database and may now be Accessed Through t 10495 2Life 3AWIRE 28TM 29 to Provide Action Healthcare Management with Innovative Mobile Health Management Solution for Patients with Chronic Conditions 10492 1Life 3AWIRE 28TM 29 to Provide Action Healthcare Management with Innovative Mobile Health Management Solution for Patients with Chronic Conditions 10492 2
... /PRNewswire-FirstCall/ -- Iomai,Corporation today...Phase 1 trial of its patch-based needle-free influ...onference call and live,webcast will be held at 8:...ts. , Conference Call Details , To access the live... Eastern Time via phone, please dial 888-396-2356 ...
... 2007 - HepaLife Technologies, Inc.,(OTCBB:HPLF) (...entific presentation of its cell based PBS-1 techn...t the "Options for the,Control of Influenza VI Con... Canada., Entitled "High titer growth of human and...embryo cell line without the need for,exogenous pr...
Other Medicine Technology:Iomai to Announce Results From Phase 1 Influenza Trial and Host,Webcast Tomorrow 2HepaLife Announces Scientific Presentation of PBS-1 Cell Line at,International Influenza Meeting 2HepaLife Announces Scientific Presentation of PBS-1 Cell Line at,International Influenza Meeting 3HepaLife Announces Scientific Presentation of PBS-1 Cell Line at,International Influenza Meeting 4HepaLife Announces Scientific Presentation of PBS-1 Cell Line at,International Influenza Meeting 5
(Date:7/25/2008)...ON, July 25 /PRNewswire/ -- The Elekta Family of C... treatment solutions at the 2008,American Associat...g,demonstrating how the joint forces of Elekta, I... therapy planning and delivery solutions that,stre...perience for,patients, as well as enhance clinicia...
(Date:7/25/2008)...ds fluid back-up in esophagus can cause immune sys...ay News) -- The first evidence linking gastroesoph...scovered by Duke University Medical Center researc...ns was first noted in the 1970s, and since then st...rcent of asthma patients also experience GERD symp...
(Date:7/25/2008)... The Retina Group of New York will...ted macular degeneration especially designed for s...e Public Library at 116 Merritts Road, Farmingdale.... Attendance is free and refreshments will be prov...6) 939-6100. , Hicksville...
(Date:7/25/2008)... This donation will be used to fac...ve services for children , ... ( www.ivci.com ), a leading integrator of enterp...tion video conferencing, telepresence, audio visua...announced today that it has donated video conferen...
Breaking Medicine News(10 mins):Health News:Elekta Family of Companies to Highlight Cancer Treatment Solutions at 2008 AAPM Annual Meeting 2Health News:Elekta Family of Companies to Highlight Cancer Treatment Solutions at 2008 AAPM Annual Meeting 3Health News:People With GERD More Likely to Develop Asthma 2Health News:Retina Group of New York To Present Seminar on Age-Related Macular Degeneration; The Leading Cause of Visual Loss in Seniors 2Health News:Retina Group of New York To Present Seminar on Age-Related Macular Degeneration; The Leading Cause of Visual Loss in Seniors 3Health News:Mt. Sinai's Children's Trauma Institute Treatment and Service Adaptation Center Receives Video Conferencing Donation From IVCi 2
... cancer often results in radiation-induced damage ..., targeted over-expression of heat shock protein 2...by Lee et al., "Radioprotective effect of HSP25 on...ished in the November issue of The American Journa...
...ilities, Health Minister Anbumani Ramadoss has bla...//, which has so far taken toll of over 130 lives ...par for the CNN-IBN programme Devil's Advocate to ...Even though I don't want to shy away from my respo...
... scientists that plays a key role in advancing inf...chers// who feel this might be the breakthrough lo...ntestinal diseases such as Crohn’s disease and ulc...een implicated with many chronic illnesses associa...
...omen who thrive on a diet which is rich in helping...he like //which is highly refined energy food gain...women who conscientiously take a diet rich in fibe...ned food is easily broken down to simple sugar, gl...
Other Medicine News:Health News:Radioprotective effect of Heat Shock Proteins 2Health News:Ramadoss Blames State Governments for High Dengue Toll 2Health News:Ramadoss Blames State Governments for High Dengue Toll 3
...ference laboratory and a worldwide leader in innov...fers an extensive test menu of highly complex and ...ology. Owned by the University of Utah, ARUP Labor...ion's university teaching hospitals and children's...
...ference laboratory and a worldwide leader in innov...fers an extensive test menu of highly complex and ...ology. Owned by the University of Utah, ARUP Labor...ion's university teaching hospitals and children's...
...ference laboratory and a worldwide leader in innov...fers an extensive test menu of highly complex and ...ology. Owned by the University of Utah, ARUP Labor...ion's university teaching hospitals and children's...
...ference laboratory and a worldwide leader in innov...fers an extensive test menu of highly complex and ...ology. Owned by the University of Utah, ARUP Labor...ion's university teaching hospitals and children's...
Medicine Products: